Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$132.03M

FY 2025 · Annual

Investing Cash Flow

$188.79M

FY 2025 · Annual

+236.5% YoY

Financing Cash Flow

-$25.75M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Depreciation & Amortization29K260K416K416K416K
Deferred Income Tax(29.39M)0(48.56M)0(6.36M)
Stock-Based Compensation39.62M46.72M49.43M51.77M20.72M
Change in Working Capital(247.85M)(46.59M)16.16M(7.48M)16.48M
Accounts Receivables00000
Inventory00000
Accounts Payables10.29M(1.98M)1.7M206K8.49M
Other Working Capital(258.13M)(44.6M)14.46M(7.68M)8M
Other Non-Cash Items29.39M(5.47M)33.11M(11.82M)(4.94M)
Operating Cash Flow(87.01M)(120.98M)(85.4M)(135.5M)(132.03M)
Capital Expenditures(4K)(1.94M)000
Acquisitions (Net)0453.47K000
Purchases of Investments0(545.35M)(562.36M)(461.18M)(281.94M)
Sales of Investments091.89M602.67M517.28M470.73M
Other Investing Activities0(453.47K)000
Investing Cash Flow(4K)(455.41M)40.3M56.11M188.79M
Debt Repayment00000
Common Stock Issued1.47M230K257K267K259K
Common Stock Repurchased0000(25.52M)
Dividends Paid00000
Other Financing Activities0140K00(485K)
Financing Cash Flow1.47M370K257K267K(25.75M)
Effect of Forex Changes00000
Net Change in Cash(85.54M)(576.02M)(44.84M)(79.13M)31.02M
Free Cash Flow(87.01M)(122.93M)(85.4M)(135.5M)(132.03M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$158.3M
+ D&A$416.0K
+ Stock-Based Comp$20.7M
- Deferred Tax-$6.4M
+ Working Capital$16.5M
- Other Non-Cash-$4.9M
= Operating Cash Flow-$132.0M
- Capex$0
= Free Cash Flow-$132.0M

Analysis

FY2025 free cash flow is -$132.0M. FCF conversion is 83.4% of net income. Operating cash flow was -$132.0M, with capex of $0. The largest bridge item is Stock-Based Comp at $20.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13GSC 13G filingOct 6, 2026

Does AVIR generate free cash flow?

Atea Pharmaceuticals, Inc. (AVIR) generated -$132.03M of free cash flow in fiscal 2025.

How much operating cash flow does AVIR produce?

Operating cash flow was -$132.03M, before capital expenditures of $0.00.